Showing results (351-360 of 745) with videos related to
Sort By:
Pageof 75
Neurogastroenterology and Motility|September 3, 2013
Postprandial symptoms originating from the stomach in functional dyspepsiaH Vanheel, T Vanuytsel, L Van Oudenhove, et al.Journal of Diabetes Science and Technology|October 16, 2013
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialAndreas Liebl, Jaime Davidson, Henriette Mersebach, et al.British Journal of Clinical Pharmacology|March 4, 2016
The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisHelena M de Wit, Maarten Te Groen, Maroeska M Rovers, et al.Biomedicines|March 28, 2025
Disease Acceptance and Control from the Subjective Health Experience Model as Health Perception Predictors in Immune-Mediated Inflammatory DiseasesTessa S Folkertsma, Sjaak Bloem, Robert M Vodegel, et al.Digestive Diseases and Sciences|September 1, 1993
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impactD A Drossman, Z Li, E Andruzzi, et al.Alimentary Pharmacology & Therapeutics|February 24, 2011
Review article: the role of gastric motility in the control of food intakeP Janssen, P Vanden Berghe, S Verschueren, et al.Magnetic Resonance in Medicine|December 4, 2003
Optimized detection of changes in glucose-6-phosphate levels in human skeletal muscle by 31P MR spectroscopyJacco H de Haan, D W J Klomp, C J Tack, et al.Neurogastroenterology and Motility|April 10, 2013
Role of duodenal mucosal nerve endings in the acid-induced duodenogastric sensorimotor reflex: effect of benzocaine in healthy humansT Vanuytsel, G Karamanolis, R Vos, et al.Chemotherapy|January 1, 1984
Antibiotic susceptibility of community hospital blood culture isolates of gram-negative bacilliR C Gordon, K J Tack, R I Haddy, et al.Life Sciences|November 29, 2005
Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptorsB Schurad, R Horowski, S Jähnichen, et al.Pageof 75